Platelet reactivity is pivotal in the pathogenesis of complications after coronary angioplasty. ADVANCE trial sought to determine whether tirofiban, administered with the high-dose bolus is able to reduce ischemic events in diabetic patients referred for elective or urgent PCI.
Tirofiban, administered at high dose bolus during coronary angioplasty is highly effective in preventing periprocedural ischemic complications in diabetic patients. Insights into the ADVANCE trial.
CAMPO, Gianluca Calogero;FERRARI, Roberto
2005
Abstract
Platelet reactivity is pivotal in the pathogenesis of complications after coronary angioplasty. ADVANCE trial sought to determine whether tirofiban, administered with the high-dose bolus is able to reduce ischemic events in diabetic patients referred for elective or urgent PCI.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
